0001140361-22-013213.txt : 20220405 0001140361-22-013213.hdr.sgml : 20220405 20220405172107 ACCESSION NUMBER: 0001140361-22-013213 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220405 DATE AS OF CHANGE: 20220405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 22808197 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 10-K/A 1 brhc10036133_10ka.htm 10-KA
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


FORM 10-K/A
Amendment No. 1
 


(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021
Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from           to_____
Commission file number: 001-37524
 

 
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)



Delaware
 
47-3916571
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
     
3980 Premier Dr, Suite 310
High Point, NC
 
27265
(Address of principal executive offices)
 
(Zip Code)

(336) 841-0300
(Registrant’s telephone number, including area code)
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each
Class
 
Trading Symbol
 
Name of each exchange on which
registered
Class A Common Stock (Par Value $0.01)
  VTVT
  NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act: None
 


Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
 
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.    Yes  ☐    No  ☒
 
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.   Yes  ☒    No  ☐
 
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).    Yes  ☒    No  ☐
 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
  Accelerated Filer
         
Non-accelerated filer
 
Smaller reporting company

         
Emerging growth company

     
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 
 
Indicate by check mark if the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒

The aggregate market value of the registrant’s Common Stock held by non-affiliates on the last business day of the Registrant’s most recently completed second quarter, June 30, 2021, was $69,158,248 (based on the closing sale price as reported on the NASDAQ).
 
Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of March 29, 2022.

Class of Stock
Shares Outstanding
Class A common stock, par value $0.01 per share
66,942,777
Class B common stock, par value $0.01 per share
23,093,860

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders to be filed within 120 days after December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.



EXPLANATORY NOTE
 
The Annual Report on Form 10-K filed by vTv Therapeutics Inc. (the “Company”) with the Securities and Exchange Commission on March 29, 2022 (the “Original 10-K”) inadvertently omitted the information set forth in “Item 9B. Other Information” of this Amendment No. 1 to Form 10-K (this “Form 10-K/A”). This Form 10-K/A is being filed solely for the purpose of including such information.
 
Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Form 10-K/A also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002.
 
Except as described above, no other changes have been made to the Original Form 10-K, and this Form 10-K/A does not modify, amend or update in any way any of the financial or other information contained in the Original Form 10-K. This Form 10-K/A does not reflect events that may have occurred subsequent to the filing of the Original Form 10-K.
 
ITEM 9B.
OTHER INFORMATION
 
On March 29, 2022, the board of directors of the Company appointed Barry Brown as Chief Accounting Officer of the Company.
 
Mr. Brown is a Certified Public Accountant and joined the Company as Controller over 20 years ago. Prior to joining the Company, Mr. Brown was Vice President and Controller for a real estate development company and, prior to that, held division Controller and other financial roles at a large textile manufacturer. Mr. Brown obtained both his MBA and Bachelor of Science in Accounting and Business Administration degrees from the University of North Carolina Greensboro.
 
There are no arrangements or understandings between Mr. Brown and any other persons pursuant to which he was selected as Chief Accounting Officer of the Company. Mr. Brown has no familial relationships with any executive officer or director of the Company. There have been no transactions in which the Company has participated and in which Mr. Brown had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.
 
ITEM 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

Exhibit
Number
 
Description
     
     
 
Certification of President and Chief Executive Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
 
Certification of Chief Accounting Officer required by Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
 
Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
 
Certification of Chief Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
104*
 
The cover page from this Annual Report on Form 10-K for the year ended December 31, 2021, formatted in Inline XBRL



*
Filed herewith
 
Auditor Name: Ernst & Young LLP
Auditor Location: Raleigh, North Carolina
Auditor PCAOB ID: 42

SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: April 5, 2022

 
VTV THERAPEUTICS INC.
 
(Registrant)
   
 
By:
/s/ Richard S. Nelson
   
Richard S. Nelson
   
Interim President and Chief Executive Officer



EX-31.1 2 brhc10036133_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

SECTION 302 CERTIFICATION

I, Richard S. Nelson, certify that:
 

1.
I have reviewed this annual report on Form 10-K of vTv Therapeutics Inc. (the “registrant”);
 

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 

(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: April 5, 2022
 
 
By:
/s/ Richard S. Nelson
 
 
Richard S. Nelson
 
 
Interim Chief Executive Officer
 


EX-31.2 3 brhc10036133_ex31-2.htm EXHIBIT 31.2
 
EXHIBIT 31.2
SECTION 302 CERTIFICATION
I, Barry Brown, certify that:
 
1.
I have reviewed this annual report on Form 10-K of vTv Therapeutics Inc. (the “registrant”);
     
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     
 
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
     
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 5, 2022
  By: /s/ Barry Brown
 
 
Barry Brown
    Chief Accounting Officer
 





EX-32.1 4 brhc10036133_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of vTv Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard S. Nelson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:


 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and

 

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 5, 2022

 

By:

/s/ Richard S. Nelson

 

Richard S. Nelson

 

Interim Chief Executive Officer

 

 


EX-32.2 5 brhc10036133_ex32-2.htm EXHIBIT 32.2

 EXHIBIT 32.2




CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of vTv Therapeutics Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Barry Brown, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: April 5, 2022

 
By: /s/ Barry Brown
 
 
Barry Brown
    Chief Accounting Officer




EX-101.SCH 6 vtvt-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 7 vtvt-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 vtvt-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Class B Common Stock [Member] Class A Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Document Annual Report Document Transition Report Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID EX-101.PRE 9 vtvt-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 29, 2022
Jun. 30, 2021
Entity Listings [Line Items]      
Document Type 10-K/A    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity Registrant Name vTv Therapeutics Inc.    
Entity Incorporation, State or Country Code DE    
Entity File Number 001-37524    
Entity Tax Identification Number 47-3916571    
Entity Address, Address Line One 3980 Premier Dr    
Entity Address, Address Line Two Suite 310    
Entity Address, City or Town High Point    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27265    
City Area Code 336    
Local Phone Number 841-0300    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Small Business true    
Entity Public Float     $ 69,158,248
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001641489    
Document Annual Report true    
ICFR Auditor Attestation Flag false    
Auditor Name Ernst & Young LLP    
Auditor Location Raleigh, North Carolina    
Auditor Firm ID 42    
Class A Common Stock [Member]      
Entity Listings [Line Items]      
Entity Common Stock, Shares Outstanding   66,942,777  
Title of 12(b) Security Class A Common Stock (Par Value $0.01)    
Trading Symbol VTVT    
Security Exchange Name NASDAQ    
Class B Common Stock [Member]      
Entity Listings [Line Items]      
Entity Common Stock, Shares Outstanding   23,093,860  
XML 11 brhc10036133_10ka_htm.xml IDEA: XBRL DOCUMENT 0001641489 2021-01-01 2021-12-31 0001641489 2021-06-30 0001641489 us-gaap:CommonClassAMember 2022-03-29 0001641489 us-gaap:CommonClassBMember 2022-03-29 0001641489 us-gaap:CommonClassAMember 2021-01-01 2021-12-31 iso4217:USD shares false --12-31 2021 FY 0001641489 NASDAQ 42 10-K/A true 2021-12-31 false 001-37524 vTv Therapeutics Inc. DE 47-3916571 3980 Premier Dr Suite 310 High Point NC 27265 336 841-0300 Class A Common Stock (Par Value $0.01) VTVT No No Yes Yes Non-accelerated Filer true false false false 69158248 66942777 23093860 Ernst & Young LLP Raleigh, North Carolina EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 5 37 1 false 2 0 false 2 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vtvtherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10036133_10ka.htm brhc10036133_ex31-1.htm brhc10036133_ex31-2.htm brhc10036133_ex32-1.htm brhc10036133_ex32-2.htm vtvt-20211231.xsd vtvt-20211231_def.xml vtvt-20211231_lab.xml vtvt-20211231_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10036133_10ka.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "vtvt-20211231_def.xml" ] }, "inline": { "local": [ "brhc10036133_10ka.htm" ] }, "labelLink": { "local": [ "vtvt-20211231_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20211231_pre.xml" ] }, "schema": { "local": [ "vtvt-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 47, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 7, "total": 7 }, "keyCustom": 0, "keyStandard": 37, "memberCustom": 0, "memberStandard": 2, "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10036133_10ka.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://vtvtherapeutics.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10036133_10ka.htm", "contextRef": "c20210101to20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class B Common Stock [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://vtvtherapeutics.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 2 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r4": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r5": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r6": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r7": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" } }, "version": "2.1" } ZIP 19 0001140361-22-013213-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-013213-xbrl.zip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end